| Market Capitalization (Millions $) |
12,379 |
| Shares
Outstanding (Millions) |
143 |
| Employees |
711 |
| Revenues (TTM) (Millions $) |
670 |
| Net Income (TTM) (Millions $) |
-272 |
| Cash Flow (TTM) (Millions $) |
58 |
| Capital Exp. (TTM) (Millions $) |
16 |
Business Description
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company based in Pasadena, California, that is focused on the development of RNA interference (RNAi) therapeutics. The company is dedicated to developing innovative therapies that target diseases with high unmet medical needs, including rare and chronic diseases such as liver diseases, cardiovascular diseases, oncology, and more.
Arrowhead's RNAi technology is based on a gene-silencing technology that uses small RNA molecules that interfere with the expression of specific genes, leading to the inhibition of the disease process. The company's leading RNAi technology platform, called TRiM (Targeted RNAi Molecule), is designed to deliver RNAi therapeutics to specific tissues and organs with high specificity, efficacy, and safety. Arrowhead's TRiM platform is specifically designed to overcome the challenges of effective delivery of RNAi drugs, including stability, targeting, and biodistribution.
The company's lead clinical development program is aimed at the treatment of liver diseases such as alpha-1 antitrypsin deficiency (AATD), hypercholesterolemia, and others. The company has also initiated clinical testing of RNAi therapeutics for cardiovascular diseases, including hypertension and pulmonary arterial hypertension (PAH), and oncology, including liver cancer (hepatocellular carcinoma) and solid tumors.
Arrowhead has collaborations with various pharmaceutical companies and academic institutions, including Takeda Pharmaceutical Company, Amgen, and The University of Texas MD Anderson Cancer Center, among others. The company's management team consists of experienced scientists, entrepreneurs, and executives, including President and CEO Christopher Anzalone, Ph.D.; Chief Medical Officer Javier San Martin, M.D.; and Chief Scientific Officer Kevin Fitzgerald, Ph.D.
Arrowhead Pharmaceuticals Inc is publicly traded on the NASDAQ market under the ticker symbol ARWR. The company has a market capitalization of over $5 billion as of August 2021, reflecting strong investor confidence in its innovative RNAi technology platform and pipeline of promising drug candidates.
Company Address: 177 E. Colorado Blvd Pasadena 91105 CA
Company Phone Number: 304-3400 Stock Exchange / Ticker: NASDAQ ARWR
|
1.75%